Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Groupopen access
- Authors
- Yoo, C.[Yoo, C.]; Im, H.-S.[Im, H.-S.]; Kim, K.-P.[Kim, K.-P.]; Oh, D.-Y.[Oh, D.-Y.]; Lee, K.-H.[Lee, K.-H.]; Chon, H.J.[Chon, H.J.]; Kim, J.H.[Kim, J.H.]; Kang, M.[Kang, M.]; Kim, I.[Kim, I.]; Lee, G.J.[Lee, G.J.]; Oh, S.Y.[Oh, S.Y.]; Choi, Y.[Choi, Y.]; Choi, H.J.[Choi, H.J.]; Kim, S.T.[Kim, S.T.]; Park, J.O.[Park, J.O.]; Ryoo, B.-Y.[Ryoo, B.-Y.]
- Issue Date
- Aug-2019
- Publisher
- SAGE Publications Inc.
- Keywords
- chemotherapy; liposomal irinotecan; pancreatic adenocarcinoma; real-world evidence
- Citation
- Therapeutic Advances in Medical Oncology, v.11
- Indexed
- SCIE
SCOPUS
- Journal Title
- Therapeutic Advances in Medical Oncology
- Volume
- 11
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/14568
- DOI
- 10.1177/1758835919871126
- ISSN
- 1758-8340
- Abstract
- Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) was effective and well-tolerated in patients with metastatic pancreatic adenocarcinoma (mPAC) that progressed on gemcitabine-based therapy in the global NAPOLI-1 trial. Real-world data may further clarify the outcomes and safety profile of nal-IRI + 5-FU/LV in clinical practice. Methods: This retrospective analysis included patients with mPAC who received nal-IRI + 5-FU/LV following gemcitabine-based therapy under a Managed Access Program in Korea. Results: From January 2017 to April 2018, 86 patients across 10 institutions received nal-IRI + 5-FU/LV (median age, 61 years; 60% male; ECOG performance status, 0–1). A total of 35 (41%) and 51 (59%) patients had received less than two and two or more lines of chemotherapy before inclusion, respectively. At a median follow up of 6.4 months, median overall survival (OS) was 9.4 months (95% confidence interval [CI] 7.4–11.4) and median progression-free survival (PFS) was 3.5 months (95% CI 1.3–5.7). Six-month OS and PFS rates were 65.1% and 37.5%, respectively. Objective response and disease control rates were 10% and 55%, respectively. Most common grade 3–4 toxicities were neutropenia (37.2%), nausea (10.5%), vomiting (9.3%), anorexia (8.1%) and diarrhoea (4.7%). Conclusion: Real-life data for Korean patients indicate that, consistent with NAPOLI-1, nal-IRI + 5-FU/LV is effective and well-tolerated in patients with mPAC that progressed on gemcitabine-based therapy. © The Author(s), 2019.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/14568)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.